STX — Shield Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £72.65m
- £86.55m
- $49.70m
Annual cashflow statement for Shield Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.1 | -49.8 | -33.3 | -27.2 | -17.7 |
| Depreciation | |||||
| Non-Cash Items | 0.564 | 19.1 | 2.84 | 5.17 | 8.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.65 | 9.98 | -7.74 | 13.8 | 4.76 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -25.1 | -18.1 | -37.1 | -6.77 | -3.38 |
| Capital Expenditures | -2.84 | -2.29 | -2.95 | -2.42 | -0.3 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.018 | 0.036 | 0.518 | 0.266 | 0.091 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2.82 | -2.25 | -2.43 | -2.15 | -0.209 |
| Financing Cash Flow Items | -0.062 | -0.403 | -0.613 | 1.52 | -4.84 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 38.1 | 8.53 | 49.7 | 1.43 | 8.63 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 12.6 | -12.9 | 10.5 | -7.42 | 5.1 |